Regulus Therapeutics Inc. (RGLS) Shares Down 6.3%

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) dropped 6.3% during mid-day trading on Friday . The stock traded as low as $1.02 and last traded at $1.05. Approximately 675,328 shares traded hands during mid-day trading, a decline of 13% from the average daily volume of 774,077 shares. The stock had previously closed at $1.12.

RGLS has been the subject of several recent research reports. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Wednesday, July 12th. Chardan Capital downgraded Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. Finally, Wedbush restated an “ourperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $3.67.

The firm’s 50-day moving average is $1.27 and its 200 day moving average is $1.21. The company’s market capitalization is $108.97 million.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. Equities analysts anticipate that Regulus Therapeutics Inc. will post ($0.96) earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. bought a new stake in Regulus Therapeutics during the third quarter valued at $347,000. EcoR1 Capital LLC boosted its stake in Regulus Therapeutics by 145.6% during the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock valued at $3,656,000 after buying an additional 2,199,144 shares during the period. Royal Bank of Canada boosted its stake in Regulus Therapeutics by 12.1% during the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 19,934 shares during the period. Goldman Sachs Group Inc. boosted its stake in Regulus Therapeutics by 189.1% during the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 240,890 shares during the period. Finally, FMR LLC boosted its stake in Regulus Therapeutics by 0.5% during the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock valued at $7,862,000 after buying an additional 37,489 shares during the period. 21.97% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Regulus Therapeutics Inc. (RGLS) Shares Down 6.3%” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2017/10/29/regulus-therapeutics-inc-rgls-shares-down-6-3.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

What are top analysts saying about Regulus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit